Recent research emphasizes the need for geoprotectors like rapamycin, which targets the mTOR pathway, to address the chronic diseases associated with aging. While life expectancy is rising, it's often accompanied by prolonged unhealthy years, prompting scientists to investigate compounds that could delay aging and improve healthspan. Rapamycin, primarily known as an immunosuppressant, has shown promise in animal models and emerging human trials for its potential to mitigate age-related conditions, thus representing a novel interest in anti-aging interventions through biological pathways rather than youth factors.
There is a growing body of research supporting the use of compounds like rapamycin to slow down aging by targeting the mTOR pathway, crucial in chronic diseases.
Animal studies and human trials suggest that rapamycin's mTOR inhibition could mitigate age-related diseases and help in extending healthspan, not just lifespan.
Collection
[
|
...
]